[Ser4(tBu)]-Cetrorelix incorporates a tert-butyl-protected serine at position four, modifying steric bulk and local hydrogen-bonding capacity. The protected residue alters polarity and retention properties during purification. Researchers examine its behavior as a synthetic intermediate and structural analog. Applications include SPPS optimization, analog comparison, and protecting-group evaluation.
CAT No: R2726
[Ser4(tBu)]-Cetrorelix is a synthetic decapeptide analog derived from the well-known gonadotropin-releasing hormone (GnRH) antagonist, Cetrorelix, featuring a tert-butyl (tBu) modification at the serine residue in position four. This structural refinement enhances its stability and bioactivity, making it an invaluable tool for researchers investigating peptide-receptor interactions, hormone regulation pathways, and peptide-based drug design. The incorporation of the tBu group provides increased resistance to enzymatic degradation, thereby extending the compound's half-life in experimental systems. As a result, [Ser4(tBu)]-Cetrorelix is recognized for its superior performance in studies requiring prolonged peptide activity and precise control over GnRH-mediated signaling events.
Receptor Binding Studies: [Ser4(tBu)]-Cetrorelix is widely utilized in receptor binding assays to elucidate the mechanisms of GnRH receptor antagonism. By offering a modified peptide structure, it allows researchers to dissect the specific contributions of side-chain alterations to receptor affinity and selectivity. This enables the mapping of critical interaction points between the ligand and the receptor, facilitating the rational design of next-generation GnRH antagonists with improved pharmacological profiles. The enhanced stability of the compound also ensures more consistent and reproducible results in in vitro binding studies, supporting the development of detailed structure-activity relationships.
Endocrine Signaling Research: The tBu-substituted analog is instrumental in probing the intricacies of endocrine signaling networks, particularly those governed by the hypothalamic-pituitary-gonadal (HPG) axis. By selectively blocking endogenous GnRH activity, it allows scientists to modulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in experimental models. This targeted inhibition provides insights into feedback mechanisms, hormonal crosstalk, and the temporal dynamics of hormone secretion. Such studies are crucial for advancing the understanding of reproductive biology and the broader field of neuroendocrinology.
Peptide Stability Assessment: The unique chemical modification present in [Ser4(tBu)]-Cetrorelix makes it an excellent candidate for evaluating peptide stability under various physiological and experimental conditions. Researchers often employ this analog to compare the degradation kinetics of modified versus unmodified peptides in the presence of proteolytic enzymes, serum, or tissue homogenates. The results of these comparative studies inform strategies for enhancing peptide durability, optimizing formulation, and improving delivery methods in peptide therapeutics research.
Molecular Modeling and Drug Design: The availability of a structurally distinct GnRH antagonist like [Ser4(tBu)]-Cetrorelix supports computational modeling and structure-based drug design efforts. Its defined modifications provide a valuable template for molecular docking studies, allowing for the exploration of conformational flexibility, binding orientations, and key molecular interactions within the GnRH receptor binding pocket. These insights enable medicinal chemists to design novel analogs with tailored properties, accelerating the discovery of innovative peptide therapeutics.
Cellular Assays and Functional Analysis: In addition to receptor and signaling studies, the tBu-modified analog is frequently incorporated into cellular assays to assess its effects on cell proliferation, hormone secretion, and downstream signaling cascades. By modulating GnRH receptor activity in cultured cells, researchers can investigate the cellular consequences of antagonism, identify off-target effects, and validate the specificity of their experimental systems. These functional assays contribute to a comprehensive understanding of GnRH antagonist biology and support the translation of basic research findings into new therapeutic strategies.
Peptide Conjugation and Delivery System Development: The robust stability and defined structure of [Ser4(tBu)]-Cetrorelix make it a promising scaffold for the development of peptide-drug conjugates and advanced delivery systems. Scientists are actively exploring its utility in conjugation chemistry, where the analog serves as a carrier for imaging agents or other bioactive molecules, enabling targeted delivery and improved pharmacokinetics. Additionally, studies on encapsulation, nanoparticle formulation, and sustained-release platforms leverage the enhanced properties of this peptide to optimize delivery and efficacy in preclinical research settings. Through these diverse applications, [Ser4(tBu)]-Cetrorelix continues to drive innovation and discovery in peptide science and biomedical research.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More